Response to Comments: MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer

This document is a response to comments on the MolDX LCD DL38647 concerning prognostic and predictive molecular classifiers for bladder cancer and lists administrative dates for the comment, notice, and effective periods. It does not contain clinical coverage, indication, limitation, or frequency criteria; those are expected to be specified in LCD DL38647 itself and should be consulted for coverage rules.

"This document is a response to comments for MolDX LCD DL38647; comment period was 2022-07-14 to 2022-08-27; notice period begins 2023-06-22; LCD effective date 2023-08-06."

Sign up to see full coverage criteria, indications, and limitations.